Asia-Pacific journal of clinical oncology最新文献

{"title":"Larotrectinib in Adjuvant and First-Line Treatment for Metastatic NTRK Fusion Colon Cancer","authors":"Alexander Y. Volkov,&nbsp;Andrey L. Pylev,&nbsp;Anna A. Zhandarova,&nbsp;Olga S. Kozlova","doi":"10.1111/ajco.70072","DOIUrl":"10.1111/ajco.70072","url":null,"abstract":"<div>\u0000 \u0000 <p>We report an 83-year-old woman with severe concomitant pathology who underwent surgery for colon cancer, with recurrent bleeding from the tumor, and subcompensated intestinal stenosis. After right-sided hemicolectomy with regional lymph node dissection, the disease was staged as pIIIC, and a translocation of the NTRK1 (Neurotrophic Tyrosine Receptor Kinase) gene was detected. The patient required adjuvant treatment, given the high risk of disease progression, but due to her severe concomitant pathology, chemotherapy was contraindicated. Adjuvant therapy with larotrectinib was recommended given NTRK gene translocation. According to examination data after three months, there was no progression. Following this, the patient decided to stop larotrectinib. Subsequently, disease progression was detected in the form of abdominal carcinomatosis, after which larotrectinib was resumed. At the time of this clinical case report, therapy is ongoing for 21 months without any signs of further disease progression. This study demonstrates the efficacy and safety of larotractinib as both adjuvant therapy and first-line therapy in a complex clinical case of colon cancer against the background of severe concomitant pathology, when chemotherapy is contraindicated.</p>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 4","pages":"618-621"},"PeriodicalIF":2.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Compassionate Access Drug Use for Solid Organ Malignancies in a Metropolitan Cancer Centre in Australia Between 2017 and 2024","authors":"Yun San Chong,&nbsp;Nicholas Yeo,&nbsp;Grace Redmayne,&nbsp;Melvin Chin","doi":"10.1111/ajco.70071","DOIUrl":"10.1111/ajco.70071","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The Pharmaceutical Benefits Scheme (PBS) provides affordable access to cancer treatments in Australia. Not all cancer treatments are available on the PBS. Access to non-PBS-listed cancer treatments can occur through Compassionate Access Programs (CAPs). This retrospective review describes cancer treatments used via CAPs in a Metropolitan Cancer Centre in Australia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with solid organ malignancies who had received drugs via compassionate access between 2017 and 2024 were identified via pharmacy and hospital medical records. Patients with hematological malignancies or who accessed drugs through out-of-pocket funding were excluded. CAPs were grouped into cost-share/co-pay and cost-free programs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 228 cases, 148 (64.9%) received the drug cost-free, and 80 (35.1%) were on a cost-share/co-pay program. A total of 110 (48.2%) patients received the CAP drug as their first therapy. The median number of previous therapies before receiving CAP drug was 1 (range: 0–4). The median duration between diagnosis and use of CAP drug was 5.1 months (range: 0.2–96.0). The median and mean duration of CAP drug use were 5.2 and 10.3 months, respectively (range: 0.03–96.0). A total of 53 programs provided 40 drugs from 18 companies. Six drugs had both cost-share/co-pay and cost-free programs. The drug with the most patients was pertuzumab (<i>n</i> = 43), followed by nivolumab (<i>n</i> = 27) and durvalumab (<i>n</i> = 21). Fourteen patients accessing non-oral drugs via cost-share/co-pay programs ultimately did not receive any free drugs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>There is an increasing prevalence of novel drug use via CAPs across all types of cancers with promising impacts on patient outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 4","pages":"501-507"},"PeriodicalIF":2.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extranodal (Nasal Variant) NK/T -Cell Lymphoma of Head and Neck: Our Experience From a Tertiary Care Centre","authors":"Manu C. Balakrishnan,&nbsp;Suvamoy Chakraborty,&nbsp;Zareen Lynrah,&nbsp;Biswajit Dey,&nbsp;Donboklang Lynser,&nbsp;Vikas Jagtap,&nbsp;Anuradha Deka,&nbsp;Sauradeep Das","doi":"10.1111/ajco.70103","DOIUrl":"10.1111/ajco.70103","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Extranodal nasal variant NK/T-cell lymphomas (ENNK) are rare, particularly in the Indian population, with limited published cohorts. This study evaluates the clinical presentation and immunohistochemical (IHC) marker profile of ENNK in Northeast India.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective review was conducted on biopsy-proven ENNK cases from January 2014 to December 2024. Age and gender distribution of the study population, different sites involved by the ENNK, symptoms’ duration &amp; presentation, IHC analysis, staging of ENNK, treatment regimen with complications, survivability analysis across different stages, and overall survival analysis were done. Descriptive statistics, chi-square analysis, and the Kaplan-Meier method for survival analysis were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Thirty-four ENNK patients were identified (median age 45; range 8–80 years; 76% male). The nose and paranasal region were affected in 76%. All cases showed Cluster of Differentiation (CD) 3 and CD 56 positivity, and Epstein-Barr virus positivity. Staging at diagnosis was: I (15%), II (73%), III (3%), and IV (9%). 59% of patients had follow-up data, with a mean survival of 24.6 ± 14.2 months (range 7–57). No statistically significant survival difference was observed across stages. Kaplan-Meier analysis demonstrated that the modified SMILE regimen (dexamethasone, methotrexate, ifosfamide, pegylated L-asparaginase, and etoposide) provided superior cumulative survival in our study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This is the first detailed ENNK cohort from Northeast India; patients referred to our center as refractory chronic sinusitis or granulomatous disease turned out to be ENNK. Practicing otorhinolaryngologists in Asia should include ENNK in differential diagnoses for early detection and improved outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 4","pages":"592-600"},"PeriodicalIF":2.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Trends and Outcomes for Localized High-Grade Soft Tissue Sarcoma: Insights from a Sarcoma Unit in Australia","authors":"Adel Shahnam,&nbsp;Jeremy Lewin,&nbsp;Anne Hamilton,&nbsp;Stephen J. Luen,&nbsp;Jayesh Desai,&nbsp;Lisa Orme,&nbsp;David Gyorki,&nbsp;Hayden Snow,&nbsp;Claudia di Bella,&nbsp;Sarah O'Reilly-Harbidge,&nbsp;Grant Pang,&nbsp;Julie Chu,&nbsp;Sarat Chander,&nbsp;Suchen Fong,&nbsp;John Slavin,&nbsp;Catherine Mitchell,&nbsp;Susie Bae","doi":"10.1111/ajco.70043","DOIUrl":"10.1111/ajco.70043","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>This study aimed to evaluate temporal trends in treatment patterns for localized soft tissue sarcomas (STSs) and identify factors associated with relapse-free survival (RFS) and overall survival (OS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective cohort study was conducted using the Australian Comprehensive Cancer Outcomes and Research Database (ACCORD) and electronic health records from a high-volume sarcoma unit. Patients aged ≥18 years with grade 3, localized STS ≥5 cm diagnosed between 2013 and 2023 were included. The cohort was divided into two periods (2013–2017 and 2018–2023) to assess changes in treatment practices. Kaplan-Meier and Cox proportional hazards models evaluated RFS and OS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 202 patients, radiation use decreased in the late period (79% vs. 64%, <i>p</i> = 0.03), with a trend toward increased systemic therapy (8% vs. 16%, <i>p</i> = 0.13). Median RFS was 19 months (95% confidence interval [CI]: 14.9–26.0), with no significant difference between periods (hazard ratio [HR] 1.30, 95% CI: 0.93–1.82, <i>p</i> = 0.13). Median OS was 48 months (95% CI: 38.1–62.9), also showing no difference (HR 1.20, 95% CI: 0.80–1.78, <i>p</i> = 0.38). Radiotherapy improved RFS (HR 0.69, 95% CI: 0.49–0.98, <i>p</i> = 0.04) but not OS. Systemic therapy showed no RFS or OS benefit. Exploratory analyses identified age, tumor size, FDG-PET SUVmax, site, and Sarculator risk as prognostic factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Treatment patterns evolved over time, reflecting emerging evidence, but no significant RFS or OS differences were observed. Further research is needed, including exploring prognostic factors like elevated baseline FDG-PET SUVmax.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 4","pages":"608-617"},"PeriodicalIF":2.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145436999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness Analysis of Hormone Therapy for Breast Cancer in Japan","authors":"Naoto Nakagawa,&nbsp;Yuta Chiba,&nbsp;Leanne Lai","doi":"10.1111/ajco.70084","DOIUrl":"10.1111/ajco.70084","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Breast cancer is one of the deadliest diseases in the world. It accounts for 22.2% of all cancers and is the most common site of cancer in women in Japan. Although hormone therapy with aromatase inhibitors or tamoxifen has been widely used, it is unclear which agent is more cost-effective. This study examined the cost-effectiveness of anastrozole as an aromatase inhibitor from a healthcare payer's perspective compared to tamoxifen in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A Markov model, for comparing anastrozole with tamoxifen as a reference agent, was developed using data from a randomized clinical trial conducted in Japan. The costs were derived from the Japanese health care fee index for 2022. Based on the results of a questionnaire on the general health-related quality of life associated with cancer (FACT-G), utilities were converted to EuroQol-5 Dimension-5 Level. The time horizon was set to 10 years. In addition, deterministic and probabilistic sensitivity analyses were conducted.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Anastrozole was dominated by tamoxifen. Deterministic one-way sensitivty analysis showed the expected value (EV) of incremental net monetary benefit for anastrozole was the highest sensitive to the pharmaceutical “drug price of anastrozole in fiscal year (FY) 2022,” where the generic drug price was applied. The EV remained negative across the other parameters. Probabilistic sensitivity analysis revealed that anastrozole dominance over tamoxifen was 47.2%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Anastrozole was less cost-effective than tamoxifen in Japan. Our findings support clinical practice and suggest that payers and policymakers should promote cost-effective therapies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 4","pages":"528-536"},"PeriodicalIF":2.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes for Patients With Micro-Invasive or Small HER2+ Breast Cancer in Northern Sydney Local Health District","authors":"Yuanyuan Xue,&nbsp;Katrina Moore,&nbsp;Tricia Saurine,&nbsp;David Chan,&nbsp;Lina Pugliano,&nbsp;Connie Diakos","doi":"10.1111/ajco.70100","DOIUrl":"10.1111/ajco.70100","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>This study aimed to review the outcomes for patients with microinvasive and small HER2+ breast cancers, compare the clinicopathological features, and explore the patterns of care.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this single-center retrospective study, patients with HER2+, pT1mic-bN0M0 disease who underwent surgery in Northern Sydney Local Health District between 2006 and 2022 were selected. The primary outcome was invasive disease-free survival (iDFS), and secondary outcome was overall survival (OS).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of the 32 eligible patients, those with pT1b disease had higher histological grades and Ki-67 indices, with a higher rate of trastuzumab administration. One recurrence and one death were observed in the pT1a group. The 5-year iDFS and OS were 93% for the pT1mic/a group and 100% for the pT1b group (<i>p</i> = 0.29). Sixty-six percent of patients received adjuvant trastuzumab. Trastuzumab prescription was associated with larger tumor sizes (<i>p</i> = 0.008) and higher histologic grades (<i>p</i> = 0.023).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with microinvasive or small HER2+ node-negative breast cancer experience favorable outcomes. The pT1b group had higher histological grades and proliferative indices. Patients with pT1b disease or higher tumor grades were more likely to receive trastuzumab. While trastuzumab is recommended for pT1b disease with strong evidence, its use in pT1a disease should be balanced against its unclear benefits and known toxicities.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":"22 4","pages":"564-572"},"PeriodicalIF":2.1,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.70100","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147472698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Joint Cancer Nurses Society of Australia-Clinical Oncology Society of Australia Position Statement on the Contribution of Nurses to Cancer Survivorship Care in Australia.","authors":"Raymond J Chan, Gemma McErlean, Fiona Crawford-Williams, Carla Thamm, Carmel O'Kane, Nicolas H Hart, Gillian Blanchard, Anne Mellon, Justin Hargreaves, Mei Krishnasamy, Michael Jefford","doi":"10.1111/ajco.70138","DOIUrl":"10.1111/ajco.70138","url":null,"abstract":"<p><strong>Aim: </strong>To describe the development, consultation, and endorsement process for a joint position statement from the Cancer Nurses Society of Australia (CNSA) and the Clinical Oncology Society of Australia (COSA) regarding the contribution of nurses to cancer survivorship care in Australia.</p><p><strong>Methods: </strong>A development team of nursing and oncology experts (n = 11) was convened in September 2025. The draft position statement was informed by key literature, including the COSA Model of Survivorship Care, Australian Cancer Plan, a modified Delphi study defining nurse capabilities in survivorship care, and an overview of systematic reviews on nurse-led care models. A consultation survey was then distributed via Qualtrics to CNSA and COSA members and partner organisations from October to November 2025. Respondents provided qualitative feedback across four domains: service delivery, research, education and policy. The expert panel incorporated the feedback and finalised the position statement, which was endorsed by COSA Council and CNSA Board in March 2026.</p><p><strong>Results: </strong>Submissions from 37 individuals and 10 organisations provided feedback on the draft position statement. Respondents were clinical nurse consultants/specialists (n = 24), nurse practitioners (n = 3), researchers (n = 2), educators (n = 1), managers (n = 3), non-nurse healthcare professionals (n = 4), and administrators of relevant not-for-profit organisations (n = 10) across Australia. Feedback was highly supportive, with respondents endorsing the statement's comprehensiveness. Key feedback included calls for greater specificity around implementation in under-resourced settings, recognition of survivorship as a nursing speciality, the need for a national survivorship minimum dataset, and emphasis on telehealth-enabled models. The final CNSA-COSA position statement articulates 40 recommendations to strengthen nursing contribution across service delivery (n = 9), research (n = 11), education (n = 9), and policy (n = 11).</p><p><strong>Conclusion: </strong>This joint CNSA-COSA position statement provides a framework to guide the integration of nursing into cancer survivorship care across Australia. Its implementation will require coordinated investment in workforce, education, research, and policy reform.</p><p><strong>Trial registration: </strong>Not applicable as this is not a clinical trial.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148359167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Real-World Safety Profiles of Fibroblast Growth Factor Receptor Inhibitors: A Pharmacovigilance Study.","authors":"Seda Jeral Evinç, Çağla Eyüpler Akmercan, Zeliha Birsin, Selin Cebeci, Emir Çerme, Vali Aliyev, Hamza Abbasov, Ebru Çiçek, Süheyla Atak, Nebi Serkan Demirci, Çiğdem Papila, Özkan Alan","doi":"10.1111/ajco.70133","DOIUrl":"https://doi.org/10.1111/ajco.70133","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to compare the real-world safety profiles of approved fibroblast growth factor receptor (FGFR) inhibitors and to identify drug-specific adverse event patterns using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).</p><p><strong>Methods: </strong>A retrospective pharmacovigilance analysis was conducted using FAERS reports submitted between January 1, 2014, and October 31, 2025. Adverse event reports involving erdafitinib, pemigatinib, futibatinib, and infigratinib were included when an FGFR inhibitor was listed as the primary suspect drug. Adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 28.0 and categorized by System Organ Class. Disproportionality analyses were performed using reporting odds ratios (RORs) with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>A total of 2081 FGFR inhibitor-related adverse event reports were identified. Erdafitinib accounted for the largest proportion of reports (53.8%), followed by pemigatinib (34.8%), futibatinib (8.2%), and infigratinib (3.2%). Overall, 69.8% of reported events were classified as serious. Infigratinib showed a markedly increased reporting likelihood for blurred vision (ROR 8.92; 95% CI: 3.73-21.36) and oral mucosal toxicity (ROR 3.38; 95% CI: 1.80-6.34). Hyperphosphatemia was most strongly associated with futibatinib (ROR 3.11; 95% CI: 1.93-5.01), whereas erdafitinib demonstrated a reduced reporting likelihood for this event (ROR 0.43; 95% CI: 0.29-0.63). Ocular adverse events, including dry eye, exhibited variable reporting patterns across agents.</p><p><strong>Conclusion: </strong>FGFR inhibitors demonstrated differences in adverse event reporting patterns rather than a uniform class effect, although pharmacovigilance data do not allow estimation of true incidence, risk, or causal relationships.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148293329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective Cohort Study of Treatment Patterns and Outcomes for Patients With Locally Advanced Rectal Cancer Across Three Metropolitan Hospitals in Brisbane.","authors":"Philip Macilwraith, Cassie Turner, Kate Roberts, Kieron Bigby, Sebastian Kang, David Wyld, Matthew Burge, Melissa Eastgate","doi":"10.1111/ajco.70124","DOIUrl":"https://doi.org/10.1111/ajco.70124","url":null,"abstract":"<p><strong>Aim: </strong>We aim to provide an overview of treatment patterns and outcomes in high-risk rectal cancer patients with a particular focus on total neoadjuvant therapy (TNT) use.</p><p><strong>Methods: </strong>Patients with locally advanced rectal cancer who commenced pre-operative treatment at the Royal Brisbane and Women's Hospital, the Princess Alexandra Hospital, and Redcliffe Hospital between 2020 and 2023 were included in this retrospective cohort study. Data collected included demographics, cancer stage, tumour details, treatment undertaken, disease progression, and survival. Data were analyzed using R Studio version 1.4.1717.</p><p><strong>Results: </strong>124 patients were included, with 47 having undergone TNT and long-course chemoradiotherapy (LCCRT) and 77 having undergone LCCRT alone ± adjuvant chemotherapy. Those who received TNT were significantly more likely to have high-risk features such as extramural venous invasion, T4 tumor, and N2 disease. 89.5% of TNT patients across our centres received FOLFOX chemotherapy, and 77.1% received ≥6 cycles. 14.7% of TNT patients went on to receive adjuvant chemotherapy compared to 35.5% of non-TNT patients, with the most common adjuvant chemotherapy in the TNT group being FOLFOX (85.7%). 15% of TNT patients achieved a pathological complete response compared with 13.8% in the non-TNT group. Disease-free survival favored the non-TNT group with a median value of 39.4 months versus 36.9 months, though this was not statistically significant.</p><p><strong>Conclusion: </strong>This retrospective cohort study undertaken across multiple metropolitan centres shows increased uptake of TNT, particularly in high-risk patient cohorts, consistent with changes in international guidelines for treatment of rectal adenocarcinoma.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148154955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Present and Future of THERANOSTICS.","authors":"Winnie Wing-Chuen Lam, Sue Ping Thang, Kelvin Siu-Hoong Loke, Pei Ing Ngam, Andrew Eik-Hock Tan, Lenith Tai-Jit Cheng, Sidney Yu, Anna Ler, Damian Li-Kin Khor, Soma Somanesan, David Chee Eng Ng","doi":"10.1111/ajco.70126","DOIUrl":"https://doi.org/10.1111/ajco.70126","url":null,"abstract":"<p><p>There is a growing worldwide interest in the detection and targeted treatment of cancer with radiotheranostics as part of precision medicine. This article reviews some of the developments in theranostics, namely, approved radiopharmaceuticals, agents in late-stage clinical trials, emerging radionuclides and targets, as well as operational and regulatory challenges. Other areas of development include use of novel ligands, new indications, and combinations with other systemic therapies. We aim to provide an overview of radiopharmaceutical therapies in use and in clinical development and consider some of the challenges in East and Southeast Asia, including an innovative yet highly regulated environment in Singapore.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148148347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}